Masimo Corp (MASI) Stock AnalysisMASIStock AnalysisMasimo Corp

Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Masimo is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is already trading essentially at the acquisition offer level around $180, which leaves very limited upside. Given the pre-market price of 179.95, the best risk/reward is poor for a fresh entry, and the situation is more of a merger-arbitrage hold than a long-term accumulation opportunity. For an impatient investor who does not want to wait for a better entry, this is a sell/no-buy setup rather than a buy.

6 analysts cover MASI: 3 rate it Buy, 3 Hold and 0 Sell. The average price target is 188.40.